Abstract Body

Background

SARS-CoV-2 infection can lead to medical comorbidities (eg, autoimmunity, vascular complications) as well as Long COVID (LC), a multisystem disease encompassing a wide range of symptoms. The biological drivers of these conditions are incompletely understood.

Methods

We performed an in-depth immunometabolic screen with multidimensional flow cytometry and plasma measurements of inflammatory biomarkers and metabolites. We compared SARS-CoV-2-naïve controls (NC, N=30) and individuals who had COVID-19 4 months prior to sampling (COVID, N=96). The post-COVID participants included those who had WHO-defined LC (LC, N=58) or had fully recovered (RC, N=38).

Results

Compared to NC, those with prior COVID-19 had an altered metabolic and inflammatory profile at 4 months post-COVID, mostly irrespective of LC symptoms. Post-COVID, we observed sustained caspase-1/4/5 activity (NC:0.95 vs COVID:1.05, p=0.0026, expressed as median of the fold change) and mitochondrial superoxide production (NC:0.9 vs COVID:1.24, p=0.005) in monocytes, indicative of inflammasome activation and oxidative stress, respectively, along with an enrichment in HLA-DRlo/p16INK4alo immature monocytes. This was accompanied by elevated inflammatory plasma biomarkers, including lipid mediators such as high arachidonic acid (NC:138 µg/mL vs COVID:268.5, p<0.0001), decreased tryptophan levels (NC:11.85 µg/mL vs COVID:9.34, p<0.0001), and alterations in the frequency of peripheral immune cell subsets. In comparison to RC participants, we identified a distinct subset of senescent effector CD8 T-cells in those who developed LC, characterized by lower expression of CD57 (RC:2311 vs LC:1344, p<0.004), an indicator of cytotoxic capacity, and higher levels of p16INK4a, a cellular senescence marker (p<0.03). Finally, a principal component analysis with the most differentiating markers demonstrated unique immunometabolic profiles in NC vs COVID groups (Figure 1A), while differences between RC and LC groups were more subtle (Figure 1B).  

Conclusions

SARS-CoV-2 infection can have a profound and sustained immunometabolic effect, which could contribute to post-acute morbidity. A combination of disjointed innate and adaptive immune recovery with metabolic alterations may contribute to LC. Our data suggest an ongoing perturbation of immunometabolic homeostasis for months following COVID-19, and could guide evaluation of treatments focused on modulating immune or metabolic pathways involved in persistent LC symptoms.